Paper Details

  1. Home
  2. Paper Details

CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

Author: GieslerKyle E, KimMichelle B, LiottaDennis C, TahirovicYesim A, TruaxValarie M, WilsonLawrence J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

CCR5 is a chemokine receptor that has become a target for treating HIV infection due to the success of Maraviroc. This review discusses the development of 'next generation' CCR5 antagonists, highlighting the most advanced candidate, Cenicriviroc, a dual CCR5/CCR2 antagonist currently in Phase II clinical studies.
Paper Details　
Original Abstract of the Article :
The chemokine receptor CCR5 has garnered significant attention in recent years as a target to treat HIV infection largely due to the approval and success of the drug Maraviroc. The side effects and inefficiencies with other first generation agents led to failed clinical trials, prompting the develop...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/27791451

データ提供：米国国立医学図書館（NLM）

CCR5 Receptor Antagonists in Preclinical to Phase II Clinical Development for HIV Treatment

The chemokine receptor CCR5 has become a significant target for HIV treatment. This review examines the current status of second-generation CCR5 antagonists in preclinical and clinical development for HIV infection. The review focuses on emerging agents and their potential to overcome the limitations of first-generation CCR5 antagonists.

Next-Generation CCR5 Antagonists: A Promising Frontier

The development of second-generation CCR5 antagonists has been driven by the need to address the side effects and inefficiencies of earlier agents. These efforts have yielded several promising candidates, including the dual CCR5/CCR2 antagonist Cenicriviroc, which is currently in phase II clinical studies.

Potential for Improved HIV Treatment

The review highlights the potential of CCR5 inhibitors, particularly the newer generation agents, to provide effective and safe treatment options for HIV infection. However, further research is needed to evaluate the long-term efficacy and safety of these agents before they can be widely adopted. This research represents a promising step forward in the ongoing quest to find effective and durable treatments for HIV.

Dr.Camel's Conclusion

This review provides a comprehensive overview of the latest advancements in CCR5 receptor antagonists for HIV treatment. The emergence of second-generation agents with improved efficacy and safety profiles offers hope for better management of HIV infection. It’s like discovering a new wellspring of knowledge in the desert of HIV research, potentially leading to more effective and enduring therapies for patients.

Date :
  1. Date Completed 2017-03-10
  2. Date Revised 2021-01-05
Further Info :

Pubmed ID

27791451

DOI: Digital Object Identifier

NIHMS932348

Related Literature

Article Analysis
・Side Effects of maraviroc
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.